BioLinq has raised $272.8M across 2 funding rounds, plus 3 undated rounds. The company is valued at $400M (post-money).
Biolinq closed a $100 million Series C round in April 2025 led by Alpha Wave Ventures, after an earlier $58 million round in 2024 that also drew participation from Niterra's venture fund and Pegasus Tech Ventures.
2 funding rounds, the latest highlighted.
BioLinq was founded in 2010, United States.
No date is disclosed for this round.
A primary round — the company sells new shares to investors it selects. $4.8M raised.
No filing has been made.
2 dated rounds, newest first.
The routes section explains what is realistically available for a company at this stage.
No. BioLinq is a private company; its shares do not trade on a public exchange.
The last valuation is $400M (post-money, Apr 2025).
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
